Dual targeting of eIF4E by blocking MNK and mTOR pathways in leukemia
- PMID: 27094611
- PMCID: PMC5065931
- DOI: 10.1016/j.cyto.2016.01.024
Dual targeting of eIF4E by blocking MNK and mTOR pathways in leukemia
Abstract
Dysregulation of mRNA translation leads to aberrant activation of cellular pathways that promote expansion and survival of leukemic clones. A key element of the initiation translation complex is eIF4E (eukaryotic translation initiation factor 4E). The mitogen-activated protein kinase (MAPK) and mammalian target of rapamycin (mTOR) pathways play important roles in the regulation of eIF4E expression and downstream functional outcomes. Mitogen-activated protein kinase interacting protein kinases (Mnks) control translation by phosphorylation of eIF4E, whereas the mTOR kinase phosphorylates/de-activates the eIF4E inhibitor, 4E-BP1, to release translational repression. Both pathways are often abnormally activated in leukemia cells and promote cell survival events by controlling expression of oncogenic proteins. Targeting these pathways may provide approaches to avoid aberrant proliferation and neoplastic transformation.
Keywords: Acute myeloid leukemia; MNK; Translation initiation; eIF4E; mTOR.
Published by Elsevier Ltd.
Figures
Similar articles
-
Signalling to eIF4E in cancer.Biochem Soc Trans. 2015 Oct;43(5):763-72. doi: 10.1042/BST20150126. Biochem Soc Trans. 2015. PMID: 26517881 Free PMC article. Review.
-
Phosphorylation of eIF4E by MNKs supports protein synthesis, cell cycle progression and proliferation in prostate cancer cells.Carcinogenesis. 2008 Dec;29(12):2279-88. doi: 10.1093/carcin/bgn221. Epub 2008 Sep 22. Carcinogenesis. 2008. PMID: 18809972
-
Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation.Mol Cell Biol. 2007 Nov;27(21):7405-13. doi: 10.1128/MCB.00760-07. Epub 2007 Aug 27. Mol Cell Biol. 2007. PMID: 17724079 Free PMC article.
-
Superoxide activates mTOR-eIF4E-Bax route to induce enhanced apoptosis in leukemic cells.Apoptosis. 2014 Jan;19(1):135-48. doi: 10.1007/s10495-013-0904-9. Apoptosis. 2014. PMID: 24052408
-
Mnks, eIF4E phosphorylation and cancer.Biochim Biophys Acta. 2015 Jul;1849(7):766-73. doi: 10.1016/j.bbagrm.2014.10.003. Epub 2014 Oct 23. Biochim Biophys Acta. 2015. PMID: 25450520 Review.
Cited by
-
NVP-2, in combination with Orlistat, represents a promising therapeutic strategy for acute myeloid leukemia.Cancer Biol Ther. 2025 Dec;26(1):2450859. doi: 10.1080/15384047.2025.2450859. Epub 2025 Jan 12. Cancer Biol Ther. 2025. PMID: 39800696 Free PMC article.
-
A Novel Bioactive Peptide, T14, Selectively Activates mTORC1 Signalling: Therapeutic Implications for Neurodegeneration and Other Rapamycin-Sensitive Applications.Int J Mol Sci. 2023 Jun 9;24(12):9961. doi: 10.3390/ijms24129961. Int J Mol Sci. 2023. PMID: 37373106 Free PMC article.
-
Inhibiting ERK/Mnk/eIF4E broadly sensitizes ovarian cancer response to chemotherapy.Clin Transl Oncol. 2018 Mar;20(3):374-381. doi: 10.1007/s12094-017-1724-0. Epub 2017 Aug 1. Clin Transl Oncol. 2018. PMID: 28766096
-
Dual targeting of glutamine and serine metabolism in acute myeloid leukemia.Front Oncol. 2024 Apr 16;14:1326754. doi: 10.3389/fonc.2024.1326754. eCollection 2024. Front Oncol. 2024. PMID: 38690164 Free PMC article.
-
Targeting mTOR signaling for the treatment of intrahepatic cholangiocarcinoma with TSC1/ARID1A mutations: a case report with an unexpected response.Ther Adv Med Oncol. 2024 Sep 13;16:17588359241271793. doi: 10.1177/17588359241271793. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 39281970 Free PMC article.
References
-
- Dash A, Gilliland DG. Molecular genetics of acute myeloid leukaemia. Best Pract Res Clin Haematol. 2001;14:49–64. - PubMed
-
- De Benedetti A, Graff JR. eIF4E expression and its role in malignancies and metastases. Oncogene. 2004;23:3189–3199. - PubMed
-
- Mamane Y, Petroulakis E, Rong L, Yoshida K, Ler LW, Sonenberg N. eIF4E — from translation to transformation. Oncogene. 2004;23:3172–3179. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous